Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 07:00 ET | Source: Adagene Inc.

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement...
April 02, 2026 06:50 ET | Source: Pharvaris N.V.

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of...
April 02, 2026 05:00 ET | Source: Immunovant Inc.

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated...
April 02, 2026 05:00 ET | Source: Roivant Sciences

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no...
April 01, 2026 18:21 ET | Source: Base Carbon Inc.

Base Carbon Annual Letter to Shareholders

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp., is pleased to...
April 01, 2026 17:00 ET | Source: Adagene Inc.

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overall survival (OS) for the 10 mg/kg cohorts was 19.4...
April 01, 2026 10:52 ET | Source: Entreprises Minières Globex Inc.

Reprise des travaux de forage sur la propriété Berrigan zinc, or, argent sous option auprès de Mines indépendantes Chibougamau

TORONTO, 01 avr. 2026 (GLOBE NEWSWIRE) -- ENTREPRISES MINIÈRES GLOBEX INC. (GMX – Bourse de Toronto, G1MN – Bourses de Francfort, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS...
April 01, 2026 10:52 ET | Source: Globex Mining Enterprises Inc.

Drilling Resumes on Globex’s Berrigan Zinc, Gold, Silver Royalty Property NW of Chibougamau, Quebec

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange,...
April 01, 2026 09:57 ET | Source: Equity Insider

The Critical Metals No One Can Replace Are Running Out of Inventory

VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- EquityInsider.com Sector Commentary — Washington just committed another $500 million to domestic critical mineral processing[1]. That...
April 01, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® Completes Domicile Change to the United States

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...